Annovis Bio, Inc. announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD). A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.31 USD | +6.72% | +35.51% | -61.23% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.23% | 75.43M | |
+4.57% | 111B | |
+11.18% | 105B | |
-12.22% | 22.34B | |
-3.99% | 21.93B | |
-6.17% | 18.59B | |
-36.52% | 18.12B | |
-9.93% | 16.96B | |
+3.14% | 13.7B | |
+36.51% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease